vs
海斯特耶鲁（HY）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是海斯特耶鲁的1.5倍（$1.4B vs $923.2M），瑞思迈净利率更高（27.6% vs -5.7%，领先33.3%），瑞思迈同比增速更快（11.0% vs -13.5%），瑞思迈自由现金流更多（$311.2M vs $32.9M），过去两年瑞思迈的营收复合增速更高（9.0% vs -6.5%）
海斯特-耶鲁物料搬运公司通过其全资运营子公司海斯特-耶鲁集团，主要以海斯特与耶鲁品牌在全球范围设计研发、生产销售全系列叉车，并提供售后配件与相关服务。该公司2002年起就在NACCO工业集团内独立运营，最终于2012年从NACCO分拆独立。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
HY vs RMD — 直观对比
营收规模更大
RMD
是对方的1.5倍
$923.2M
营收增速更快
RMD
高出24.5%
-13.5%
净利率更高
RMD
高出33.3%
-5.7%
自由现金流更多
RMD
多$278.3M
$32.9M
两年增速更快
RMD
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $923.2M | $1.4B |
| 净利润 | $-52.5M | $392.6M |
| 毛利率 | 14.2% | 61.8% |
| 营业利润率 | -4.0% | 34.6% |
| 净利率 | -5.7% | 27.6% |
| 营收同比 | -13.5% | 11.0% |
| 净利润同比 | -609.7% | 13.9% |
| 每股收益（稀释后） | $-2.97 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HYRMD
| Q4 25 | $923.2M | $1.4B | ||
| Q3 25 | $979.1M | $1.3B | ||
| Q2 25 | $956.6M | $1.3B | ||
| Q1 25 | $910.4M | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.1B | $1.2B |
净利润HYRMD
| Q4 25 | $-52.5M | $392.6M | ||
| Q3 25 | $-2.3M | $348.5M | ||
| Q2 25 | $-13.9M | $379.7M | ||
| Q1 25 | $8.6M | $365.0M | ||
| Q4 24 | $10.3M | $344.6M | ||
| Q3 24 | $17.2M | $311.4M | ||
| Q2 24 | $63.3M | $292.2M | ||
| Q1 24 | $51.5M | $300.5M |
毛利率HYRMD
| Q4 25 | 14.2% | 61.8% | ||
| Q3 25 | 15.9% | 61.5% | ||
| Q2 25 | 17.6% | 60.8% | ||
| Q1 25 | 19.5% | 59.3% | ||
| Q4 24 | 19.4% | 58.6% | ||
| Q3 24 | 19.0% | 58.6% | ||
| Q2 24 | 22.2% | 58.5% | ||
| Q1 24 | 22.3% | 57.9% |
营业利润率HYRMD
| Q4 25 | -4.0% | 34.6% | ||
| Q3 25 | 0.2% | 33.4% | ||
| Q2 25 | -0.9% | 33.7% | ||
| Q1 25 | 2.3% | 33.0% | ||
| Q4 24 | 3.0% | 32.5% | ||
| Q3 24 | 3.3% | 31.6% | ||
| Q2 24 | 8.2% | 31.2% | ||
| Q1 24 | 7.9% | 31.3% |
净利率HYRMD
| Q4 25 | -5.7% | 27.6% | ||
| Q3 25 | -0.2% | 26.1% | ||
| Q2 25 | -1.5% | 28.2% | ||
| Q1 25 | 0.9% | 28.3% | ||
| Q4 24 | 1.0% | 26.9% | ||
| Q3 24 | 1.7% | 25.4% | ||
| Q2 24 | 5.4% | 23.9% | ||
| Q1 24 | 4.9% | 25.1% |
每股收益（稀释后）HYRMD
| Q4 25 | $-2.97 | $2.68 | ||
| Q3 25 | $-0.13 | $2.37 | ||
| Q2 25 | $-0.79 | $2.58 | ||
| Q1 25 | $0.48 | $2.48 | ||
| Q4 24 | $0.57 | $2.34 | ||
| Q3 24 | $0.97 | $2.11 | ||
| Q2 24 | $3.58 | $1.97 | ||
| Q1 24 | $2.93 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | $251.9M | $403.9M |
| 股东权益账面价值 | $472.0M | $6.3B |
| 总资产 | $2.0B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.53× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资HYRMD
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $932.7M | ||
| Q4 24 | — | $521.9M | ||
| Q3 24 | — | $426.4M | ||
| Q2 24 | — | $238.4M | ||
| Q1 24 | — | $237.9M |
总债务HYRMD
| Q4 25 | $251.9M | $403.9M | ||
| Q3 25 | $252.2M | $408.7M | ||
| Q2 25 | $245.2M | $658.4M | ||
| Q1 25 | $242.6M | $663.1M | ||
| Q4 24 | $241.9M | $662.9M | ||
| Q3 24 | $247.4M | $667.6M | ||
| Q2 24 | $248.5M | $697.3M | ||
| Q1 24 | $239.7M | $997.0M |
股东权益HYRMD
| Q4 25 | $472.0M | $6.3B | ||
| Q3 25 | $536.0M | $6.1B | ||
| Q2 25 | $544.7M | $6.0B | ||
| Q1 25 | $510.0M | $5.5B | ||
| Q4 24 | $475.1M | $5.3B | ||
| Q3 24 | $529.9M | $5.2B | ||
| Q2 24 | $465.7M | $4.9B | ||
| Q1 24 | $412.1M | $4.6B |
总资产HYRMD
| Q4 25 | $2.0B | $8.5B | ||
| Q3 25 | $2.1B | $8.3B | ||
| Q2 25 | $2.1B | $8.2B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.0B | $7.1B | ||
| Q3 24 | $2.2B | $7.2B | ||
| Q2 24 | $2.1B | $6.9B | ||
| Q1 24 | $2.1B | $6.8B |
负债/权益比HYRMD
| Q4 25 | 0.53× | 0.06× | ||
| Q3 25 | 0.47× | 0.07× | ||
| Q2 25 | 0.45× | 0.11× | ||
| Q1 25 | 0.48× | 0.12× | ||
| Q4 24 | 0.51× | 0.13× | ||
| Q3 24 | 0.47× | 0.13× | ||
| Q2 24 | 0.53× | 0.14× | ||
| Q1 24 | 0.58× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.5M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $32.9M | $311.2M |
| 自由现金流率自由现金流/营收 | 3.6% | 21.9% |
| 资本支出强度资本支出/营收 | 2.6% | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.87× |
| 过去12个月自由现金流最近4个季度 | $23.6M | $1.8B |
8季度趋势，按日历期对齐
经营现金流HYRMD
| Q4 25 | $56.5M | $339.7M | ||
| Q3 25 | $37.1M | $457.3M | ||
| Q2 25 | $28.9M | $538.8M | ||
| Q1 25 | $-36.4M | $578.7M | ||
| Q4 24 | $80.7M | $308.6M | ||
| Q3 24 | $70.1M | $325.5M | ||
| Q2 24 | $-2.5M | $440.1M | ||
| Q1 24 | $22.4M | $402.0M |
自由现金流HYRMD
| Q4 25 | $32.9M | $311.2M | ||
| Q3 25 | $22.6M | $414.4M | ||
| Q2 25 | $15.1M | $508.2M | ||
| Q1 25 | $-47.0M | $557.9M | ||
| Q4 24 | $62.8M | $288.0M | ||
| Q3 24 | $59.9M | $307.7M | ||
| Q2 24 | $-14.7M | $415.2M | ||
| Q1 24 | $14.9M | $380.8M |
自由现金流率HYRMD
| Q4 25 | 3.6% | 21.9% | ||
| Q3 25 | 2.3% | 31.0% | ||
| Q2 25 | 1.6% | 37.7% | ||
| Q1 25 | -5.2% | 43.2% | ||
| Q4 24 | 5.9% | 22.5% | ||
| Q3 24 | 5.9% | 25.1% | ||
| Q2 24 | -1.3% | 33.9% | ||
| Q1 24 | 1.4% | 31.8% |
资本支出强度HYRMD
| Q4 25 | 2.6% | 2.0% | ||
| Q3 25 | 1.5% | 3.2% | ||
| Q2 25 | 1.4% | 2.3% | ||
| Q1 25 | 1.2% | 1.6% | ||
| Q4 24 | 1.7% | 1.6% | ||
| Q3 24 | 1.0% | 1.5% | ||
| Q2 24 | 1.0% | 2.0% | ||
| Q1 24 | 0.7% | 1.8% |
现金转化率HYRMD
| Q4 25 | — | 0.87× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | -4.23× | 1.59× | ||
| Q4 24 | 7.83× | 0.90× | ||
| Q3 24 | 4.08× | 1.05× | ||
| Q2 24 | -0.04× | 1.51× | ||
| Q1 24 | 0.43× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HY
| Sales Channel Through Intermediary | $281.7M | 31% |
| Aftermarketsales | $179.1M | 19% |
| Sales Channel Directly To Consumer | $173.6M | 19% |
| EMEAHY | $153.3M | 17% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $89.0M | 10% |
| Otherrevenue | $42.4M | 5% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
